Estimation of 8-iso-PGF2α as a marker of oxidative stress in T2DM patients with and without dyslipidemia

Read full text Summarise with VIRAT
Authors: Najlaa Qassim Muftin, Ghasaq J. Kashtl
Cited by: 0
References: 34

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Oxidative stress resulting from excessive production of reactive oxygen species (ROS) plays a pivotal role in the development of chronic diseases, including type 2 diabetes mellitus (T2DM) and its related metabolic disturbances. This study aimed to assess the biomarker 8-iso-prostaglandin-F2α (8-iso-PGF2α) as an indicator of oxidative stress in T2DM patients and to investigate its association with dyslipidemia, with the objective of determining its potential value in predicting early diabetesrelated complications. The study included 90 participants: 60 T2DM patients (30 with dyslipidemia and 30 without) and 30 age and sexmatched healthy controls. Fasting serum samples were analyzed for glucose and lipid profile using an autoanalyzer, while C-reactive protein (CRP) and 8-iso-PGF2α levels were measured using ELISA. Compared with healthy controls, patients with T2DM exhibited markedly elevated levels of oxidative stress and inflammatory markers, including significant increases in both 8-iso-PGF2α and CRP. Among individuals with T2DM, those with dyslipidemia showed substantially higher 8-iso-PGF2α concentrations and a slightly higher CRP levels compared with patients without dyslipidemia. Diagnostic assessment indicated that 8-iso-PGF2α showed moderate ability to distinguish T2DM patients with dyslipidemia from those without. These findings suggest that elevated 8-iso-PGF2α, particularly in dyslipidemic T2DM patients, may serve as a promising early marker for assessing the risk of T2DMassociated complications.

Fields of Study & Subjects

Antioxidant Activity and Oxidative Stress Diabetes Cardiovascular Risks and Lipoproteins Adipokines Inflammation and Metabolic Diseases

Publication details

Journal / source
Current Issues in Pharmacy and Medical Sciences
Volume
39
Issue
1
Pages
1–1
Publication date
31 March 2026
Language
EN